Bone Biologics Corporation — Form 8-K Summary
Reporting event: Annual Meeting held September 28, 2026; the 8-K was signed September 29, 2026. This filing reports stockholder votes, not quarterly or annual financial results.
Meeting participation
Of 2,011,057 shares entitled to vote, 951,746 were present or represented by proxy. The filing provides no revenue, profit, cash flow, margin, debt, or liquidity data.
Voting results and material matters
- Directors: Stockholders elected Bruce Stroever, Siddhesh Angle, Robert Gagnon, and Philip Meikle. Votes for ranged from 152,615 to 158,799; each nominee received 758,866 broker non-votes.
- Executive compensation: Approved on an advisory basis, with 139,592 votes for and 49,851 against.
- Auditor: Ratified Weinberg & Company, P.A. as independent auditor for the fiscal year ending December 31, 2026; 898,011 votes for and 49,834 against.
- Warrant-share issuance: Approved, for Nasdaq Listing Rule 5635(d) purposes, potential issuance of common shares underlying certain warrants issued under the July 7, 2026 Securities Purchase Agreement and related engagement letter. The authorized potential issuance may equal or exceed 20% of the common shares outstanding immediately before the warrants were issued.
- Reverse stock split: Approved a charter amendment authorizing a reverse split between 1-for-2 and 1-for-10, at the board’s discretion. Approval does not establish that or when a split will occur.
- Adjournment: Approved, but an adjournment was unnecessary because the other specified proposals passed.
Outlook, risks, and items to verify
The filing gives no financial guidance or management outlook. The principal corporate actions to monitor are the board’s decision on whether and at what ratio to implement the reverse split, and any issuance of shares under the approved warrant arrangements. The filing does not state the number of shares potentially issuable under those warrants.
- Verify any subsequent board action, timing, and final ratio for a reverse split.
- Review the July 7, 2026 Securities Purchase Agreement, amended engagement letter, and warrant terms for potential dilution and issuance conditions.
- Consult the company’s financial filings for current operating results, cash position, financing needs, and liquidity information, which are not included in this 8-K.